KPV

No human trial of KPV has ever been registered — the evidence base is entirely mouse colitis and skin-inflammation models, cell culture work on its NF-κB-blocking mechanism, and one study using human skin removed and tested in the lab. In those preclinical models it consistently reduces inflammation and preserves gut-barrier proteins, but nothing in the published record shows what it does in a living person.

The research was built around oral and topical use, not injection. KPV is actively transported across the gut lining by the PepT1 transporter, which is specifically what let researchers dose it orally in mouse colitis models and have it act directly on inflamed intestinal tissue — a route most peptides can't use because digestion destroys them. Injection under the skin is, notably, the one route the actual research never took; the self-administered injectable use that circulates in practice has no supporting study of its own.

Mouse dosing doesn't translate cleanly to a human figure: colitis studies used either a concentration in drinking water with no measured intake per animal, or injections into the abdominal cavity at roughly 10 µg per mouse a day — scaling that to human body weight arithmetically gives 28–36 mg, but that conversion was never properly validated. The 250–500 µg a day used in self-administration outside any trial is circulating practice, not a research-derived figure, and it uses the one route — injection — the actual studies didn't test.

In preclinical studies KPV has been well tolerated, without the general immune suppression seen with some anti-inflammatory approaches, and without the skin-darkening, appetite suppression or sexual effects that come from full-length α-MSH's melanocortin receptor activity, since KPV doesn't bind those receptors. That said, comprehensive human safety data doesn't exist yet — what's available is extrapolated from the established safety record of α-MSH and related melanocortin peptides, not measured for KPV itself in people.

For arthritis, this rests on extrapolation rather than direct evidence: no published study has tested KPV itself in an arthritis model or examined its effect on joint inflammation signalling — the idea comes from KPV's relationship to α-MSH, whose anti-inflammatory activity is broadly credited to this same sequence. For neuroinflammation the gap is larger still: no study was found testing whether KPV even crosses the blood-brain barrier, let alone reduces neuroinflammation in any model.

KPV has no FDA or other regulatory approval and has not gone through formal clinical trials as a standalone therapy — it's classified as an investigational research compound. It is not on WADA's prohibited list and is not a scheduled or controlled substance anywhere.

As a small tripeptide it is more stable than larger peptides: the lyophilised powder holds up 24 months or more at −20 °C, or up to 12 months at 2–8 °C. It has no cysteine or methionine residues, so it resists oxidation, and its proline residue adds some resistance to enzymatic breakdown; once reconstituted, the solution is kept at 2–8 °C and used within 28 days.